BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27924922)

  • 21. Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer.
    Cercek A; Shia J; Gollub M; Chou JF; Capanu M; Raasch P; Reidy-Lagunes D; Proia DA; Vakiani E; Solit DB; Saltz LB
    Clin Colorectal Cancer; 2014 Dec; 13(4):207-12. PubMed ID: 25444464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KRAS and aneusomy of chromosomes 4, 10 and 12 in colorectal carcinomas.
    Beyer K; Altendorf-Hofmann A; Chen Y; Bickel K; Petersen I
    Pathol Res Pract; 2015 Sep; 211(9):646-51. PubMed ID: 26122820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.
    Takahashi N; Yamada Y; Taniguchi H; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
    Arch Med Res; 2014 Jul; 45(5):366-74. PubMed ID: 24830936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-resolution melting assay (HRMA) is a simple and sensitive stool-based DNA Test for the detection of mutations in colorectal neoplasms.
    Li BS; Wang XY; Xu AG; Ma FL; Ma QY; Li Z; Liu JH; Gan AH; Yu ZJ; Zhang XH; Jiang B
    Clin Colorectal Cancer; 2012 Dec; 11(4):280-90. PubMed ID: 22609129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrating
    Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
    World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
    Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW
    Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BCL10 as a useful marker for pancreatic acinar cell carcinoma, especially using endoscopic ultrasound cytology specimens.
    Hosoda W; Sasaki E; Murakami Y; Yamao K; Shimizu Y; Yatabe Y
    Pathol Int; 2013 Mar; 63(3):176-82. PubMed ID: 23530562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LEF-1 is frequently expressed in colorectal carcinoma and not in other gastrointestinal tract adenocarcinomas: an immunohistochemical survey of 602 gastrointestinal tract neoplasms.
    Kermanshahi TR; Jayachandran P; Chang DT; Pai R
    Appl Immunohistochem Mol Morphol; 2014; 22(10):728-34. PubMed ID: 25394300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Relationship between E-CD and Snail expressions and tumor invasion, metastasis and prognosis in colorectal cancer].
    Zheng BA; Deng GL; Dong QJ; Zhao ZS; Deng YC
    Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):111-6. PubMed ID: 20403241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
    Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
    J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of mucinous and necrotic tissue in colorectal cancer samples on KRAS mutation analysis.
    Büttner J; Lehmann A; Klauschen F; Hummel M; Lenze D; Dietel M; Jöhrens K
    Pathol Res Pract; 2017 Jun; 213(6):606-611. PubMed ID: 28551386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
    Alamo P; Gallardo A; Di Nicolantonio F; Pavón MA; Casanova I; Trias M; Mangues MA; Lopez-Pousa A; Villaverde A; Vázquez E; Bardelli A; Céspedes MV; Mangues R
    FASEB J; 2015 Feb; 29(2):464-76. PubMed ID: 25359494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathologic, molecular, and prognostic implications of the loss of EPCAM expression in colorectal carcinoma.
    Kim JH; Bae JM; Song YS; Cho NY; Lee HS; Kang GH
    Oncotarget; 2016 Mar; 7(12):13372-87. PubMed ID: 26528695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy.
    Alves S; Castro L; Fernandes MS; Francisco R; Castro P; Priault M; Chaves SR; Moyer MP; Oliveira C; Seruca R; Côrte-Real M; Sousa MJ; Preto A
    Oncotarget; 2015 Oct; 6(31):30787-802. PubMed ID: 26418750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival.
    Olevian DC; Nikiforova MN; Chiosea S; Sun W; Bahary N; Kuan SF; Pai RK
    Hum Pathol; 2016 Mar; 49():124-34. PubMed ID: 26826419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The importance of mitochondrial folate enzymes in human colorectal cancer.
    Miyo M; Konno M; Colvin H; Nishida N; Koseki J; Kawamoto K; Tsunekuni K; Nishimura J; Hata T; Takemasa I; Mizushima T; Doki Y; Mori M; Ishii H
    Oncol Rep; 2017 Jan; 37(1):417-425. PubMed ID: 27878282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer.
    Jones RP; Sutton PA; Evans JP; Clifford R; McAvoy A; Lewis J; Rousseau A; Mountford R; McWhirter D; Malik HZ
    Br J Cancer; 2017 Mar; 116(7):923-929. PubMed ID: 28208157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
    Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
    Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of S100A4 mRNA and protein expression in colorectal cancer.
    Kang YG; Jung CK; Lee A; Kang WK; Oh ST; Kang CS
    J Surg Oncol; 2012 Feb; 105(2):119-24. PubMed ID: 21837681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.